{"entity":{"id":"minnesota-masonic","kind":"institution","name":"Masonic Cancer Center, University of Minnesota","aka":[],"tldr":"The Masonic Cancer Center is where Robert Good performed the first successful human bone marrow transplant in 1968; today Jeffrey Miller's group runs natural killer cell therapy trials, and Stephen Hecht's laboratory defined the tobacco-specific carcinogens used in tobacco regulation.","summary":"NCI comprehensive since 1998, the Masonic Cancer Center inherits the University of Minnesota's transplant legacy: Robert Good performed the first successful human bone marrow transplant here in 1968, and John Wagner's group pioneered unrelated cord blood transplantation. Jeffrey Miller's programme ran the first haploidentical natural killer cell infusions in leukaemia and now partners with Fate Therapeutics on iPSC-derived NK products; Daniel Vallera's tri-specific killer engagers extend the NK concept. Stephen Hecht's laboratory defined the tobacco-specific carcinogens and biomarkers used in tobacco regulation. Clinical care is delivered through M Health Fairview.","asOf":"2026-09-09","links":[{"label":"Masonic Cancer Center","url":"https://cancer.umn.edu"}],"tags":[],"related":[],"cancers":["aml","all-leukemia"],"sections":["cell-therapy","prevention"],"technologies":["allogeneic-hsct","car-nk-macrophage","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":["fate-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jeffrey-miller"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Minneapolis, MN","country":"US","lat":44.973,"lng":-93.233,"institutionType":"cancer-center","website":"https://cancer.umn.edu","nci":"comprehensive","university":"University of Minnesota","programs":["Transplant and cord blood","NK cell therapy","Tobacco carcinogenesis"]},"route":"/institutions/minnesota-masonic/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/"}],"company":[{"id":"fate-therapeutics","kind":"company","name":"Fate Therapeutics","route":"/companies/fate-therapeutics/"}],"person":[{"id":"jeffrey-miller","kind":"person","name":"Jeffrey Miller","route":"/people/jeffrey-miller/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"collection":[{"id":"nci-cancer-centers","kind":"collection","name":"NCI-Designated Cancer Centers","route":"/collections/nci-cancer-centers/"}]}}